You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ)2020年度淨利潤預增590%-620% 13價肺炎球菌多糖結合疫苗成功上市新增銷售收入16億元
格隆匯 01-27 20:06

格隆匯 1 月 27日丨沃森生物(300142.SZ)公佈,預計2020年度營業收入28.5億元-29.4億元,同比增長154.19%-162.21%;歸屬於上市公司股東的淨利潤9.8億元-10.22億元,同比增長590%-620%;扣除非經常性損益後的淨利潤6.9億元-7.3億元,同比增長438%-469%。

2020年度業績變動影響主要因素如下:1. 公司新產品、新項目研發投入增加,研發項目進展順利,研發費用較去年期增長215%

2. 公司強化生產管理,自主生產疫苗產品產量穩定增長,疫苗產品批簽發去年同期增加12%

3. 公司持續加大對國內外疫苗市場拓展力度,加強營銷管理銷售費用同比增加,同時,公司自主生產疫苗產品銷售收入持續增長,與去年同期相比增長154%162%,其中,公司自主研發生產13價肺炎球菌多糖結合疫苗成功上市銷售,新增銷售收入約16億元;原有疫苗產品銷量、收入較上年同期增加

4. 公司持有嘉和生物藥業(開曼)控股有限公司股權於202010月正式在香港聯合交易所上市,報吿期內確認該股權公允價值變動增加額2.5億元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account